Letrozolo Alter (Letrozole)

Letrozole blocks the aromatase enzyme, which converts androgens into estrogens. By inhibiting this conversion, estrogen levels fall, reducing the growth stimulus for estrogen‑dependent breast cancer cells.

The specific dose and regimen are determined by the prescribing physician based on the patient’s clinical condition, treatment stage, and individual factors. No fixed dose is provided here.

Letrozolo Alter is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy. It is also not recommended for breastfeeding women because it may pass into breast milk and affect the infant.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Letrozole belongs to the aromatase inhibitor class, which directly lowers estrogen production, unlike selective estrogen receptor modulators such as tamoxifen that block estrogen receptors. Aromatase inhibitors are generally preferred for postmenopausal patients due to higher efficacy in this population.

Store Letrozolo Alter at ambient temperature, below 25 °C, in the original packaging. Keep it away from moisture, direct sunlight, and excessive heat to maintain product stability.

Letrozolo Alter is taken orally, usually as a tablet swallowed with water. The exact timing (e.g., with or without food) should follow the prescribing physician’s instructions.

Serious risks include severe liver injury, osteoporotic fractures, and thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Patients should be monitored regularly for signs of these conditions.

Letrozolo Alter should not be used by pregnant women, individuals with known hypersensitivity to letrozole, or patients with severe hepatic impairment without careful monitoring. It is also contraindicated in premenopausal women unless ovarian function suppression is confirmed.